Roche: EU OKs Tecentriq for lung cancer
(CercleFinance.com) - The European Commission has approved Roche's immunotherapy Tecentriq for the initial treatment of patients with the most common form of advanced lung cancer.
The EU has approved and granted marketing authorisation for Tecentriq, in combination with chemotherapy, for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.
This approval is based on results from a Phase III study, which showed that the Tecentriq combination therapy helped people live significantly longer, compared with chemotherapy alone.
The Commission also approved Tecentriq, in combination with chemotherapy, for the initial treatment of people with extensive-stage small cell lung cancer, making it the first immunotherapy available in Europe for this kind of cancer.
Lung cancer is the leading cause of cancer death globally.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The EU has approved and granted marketing authorisation for Tecentriq, in combination with chemotherapy, for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.
This approval is based on results from a Phase III study, which showed that the Tecentriq combination therapy helped people live significantly longer, compared with chemotherapy alone.
The Commission also approved Tecentriq, in combination with chemotherapy, for the initial treatment of people with extensive-stage small cell lung cancer, making it the first immunotherapy available in Europe for this kind of cancer.
Lung cancer is the leading cause of cancer death globally.
Copyright (c) 2019 CercleFinance.com. All rights reserved.